Methods:
This retrospective cohort study of a group of patients with high PSA was initiated in 2012–2013 when 243 patients were admitted to Sina hospital. They were visited and their demographic and clinical information was collected at baseline. As well, Serum concentration of B2MG was measured. Study participants were followed up to 5five years and they were classified into three groups of normal, BPH, and prostate cancer on the basis of their pathology reports. The criteria for entry in to the study werewhere patients underwent RP by expert urologist and had no evidence of metastasis in preoperative evaluation. Exclusion criteria include high creatinine (≥1.5), Radiotherapy or Androgen Deprivation Therapy (ADT) prior to onset of BCR, concomitant cancer, increased Gleason score in post RP pathology, BMI> 30 , diseases associated with immune involvement and Non prostatenon-prostate cancer related deathdeaths. There were 59 final cases that underwent RP and were followed up during telephone calls and their periodic clinical checkupscheck-ups information. PSA rising was reassessed in 2018. consideringConsidering the primary T stage based on DRE findings, serum PSA level and Gleason score, there are several classification schemes that have been proposed that correlate with clinical outcomes.in In this study, according to D’Amico classification, we categorized patients by pretreatmentpre-treatment parameters to low risk (clinical stage T1 to 2a ,PSA≤10ng/ml and Gleason score ≤ 6), intermediate-risk( stageintermediate-risk (stage T2b or PSA >10 but <20 ng/mL or Gleason score 7) and high risk group (stage T2c, or PSA>20 ng/mL or Gleason score 8to 10).
Study data were entered into IBM SPSS Statistics, version 21 and statistical analysis were performed. Mean and standard deviation are used to describe the continuescontinuous variables, and values number, and frequency percentage that were used for categorical data.